Stocks and Investing Stocks and Investing
Mon, August 5, 2024

Matt Miksic Maintained (TNDM) at Buy with Increased Target to $58 on, Aug 5th, 2024


Published on 2024-10-28 13:12:26 - WOPRAI, Matt Miksic
  Print publication without navigation


Matt Miksic of Barclays, Maintained "Tandem Diabetes Care, Inc." (TNDM) at Buy with Increased Target from $55 to $58 on, Aug 5th, 2024.

Matt has made no other calls on TNDM in the last 4 months.



There are 9 other peers that have a rating on TNDM. Out of the 9 peers that are also analyzing TNDM, 1 agrees with Matt's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Jeff Johnson of "Baird" Maintained at Hold with Increased Target to $39 on, Friday, August 2nd, 2024


These are the ratings of the 8 analyists that currently disagree with Matt


  • Larry Biegelsen of "Wells Fargo" Maintained at Buy with Increased Target to $55 on, Friday, August 2nd, 2024
  • Matt O'Brien of "Piper Sandler" Reiterated at Buy with Increased Target to $55 on, Friday, August 2nd, 2024
  • Steven Lichtman of "Oppenheimer" Maintained at Buy with Increased Target to $58 on, Monday, June 10th, 2024
  • Issie Kirby of "Redburn Atlantic" Initiated at Strong Buy and Held Target at $60 on, Thursday, May 30th, 2024
  • Mathew Blackman of "Stifel" Maintained at Strong Buy with Increased Target to $60 on, Wednesday, May 29th, 2024
  • Brooks O'Neil of "Lake Street" Maintained at Strong Buy with Increased Target to $75 on, Wednesday, May 22nd, 2024
  • Joanne Wuensch of "Citigroup" Upgraded from Hold to Strong Buy and Increased Target to $57 on, Wednesday, May 22nd, 2024
  • Mike Kratky of "Leerink Partners" Upgraded from Hold to Buy and Increased Target to $45 on, Thursday, April 25th, 2024
Contributing Sources